| Item type |
学術雑誌論文 / Journal Article(1) |
| タイトル |
|
|
タイトル |
Comparisons of Therapeutic Effects of Allopurinol and Febuxostat in Chronic Hemodialysis Patients |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
uric acid |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
hyperuricemia |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
hemodialysis |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
xanthine oxidase inhibitor |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
febuxostat |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Nagase, Akihiko
Ishimitsu, Toshihiko
Furuichi, Masahito
Onoda, Shou
Ohira, Takehiro
Murayama, Yoshiki
Tojo Akihiro
|
| 著者所属 |
|
|
|
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan |
| 著者所属 |
|
|
|
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan |
| 著者所属 |
|
|
|
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan |
| 著者所属 |
|
|
|
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan |
| 著者所属 |
|
|
|
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan |
| 著者所属 |
|
|
|
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan |
| 著者所属 |
|
|
|
Department of Nephrology and Hypertension, Dokkyo Medical University, Mibu, Tochigi, Japan |
| 書誌情報 |
Dokkyo Journal of Medical Sciences
巻 46,
号 1,
p. 17-27,
発行日 2019-03-25
|
| 要旨 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
More than few patients on maintenance hemodialysis present with hyperuricemia, and the control of serum uric acid level is an important issue in the long-term management. In addition to allopurinol, febuxostat can be used as a xanthine oxidase inhibitor in hemodialysis patients. In this study, the clinical effects of febuxostat were compared with allopurinol in chronic hemodialysis patients. Eligible hemodialysis patients taking allopurinol were randomly assigned to take 100 mg allopurinol（n＝26）or 20 mg febuxostat（n＝23）for 12 weeks. Serum uric acid was markedly lowered in the febuxostat group（0-week 6.7 mg/dL, 12-week 4.3 mg/dL, p＜0.001）as compared with the allopurinol group（0-week 6.0 mg/dL, 12-week 5.8 mg/dL）and systolic blood pressure was lowered by 5 mmHg（p＝0.036）at 4-week in the febuxostat group while blood pressure was not significantly changed in the allopurinol group throughout the study period. In addition, the dose of erythropoiesis stimulating agent was reduced（0-week 22.2 μg/wk, 12-week, 17.1 μg/wk, p＝0.012）and serum phosphate level was lowered（0-week 5.9 mg/dL, 12-week 5.1 mg/dL, p＝0.027）in the febuxostat group but not in the allopurinol group. It is concluded that febuxostat is more effective in lowering serum uric acid than allopurinol in hemodialysis patients. In addition, it is suggested that febuxostat has an advantage in the management of renal anemia and hyperphosphatemia as well as hyperuricemia. |
| 記事種別 |
|
|
|
Original |
| 出版者 |
|
|
出版者 |
獨協医学会 |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
03855023 |
DJMS-46-1-Nagase-本文 (307.5 kB)
